| Rocky Mountain Hospice-butte 19 Discovery Dr, Butte, MT, 59701 | |
| (406) 494-6114 |
News Archive
The most comprehensive analysis yet of breast cancer shows that one of the most deadly subtypes is genetically more similar to ovarian tumors than to other breast cancers.
Data showing the ability of omacetaxine to kill leukemic stem cells in mouse models with drug-resistant chronic myelogenous leukemia (CML) are the subject of an advance online publication in the journal Leukemia, ChemGenex Pharmaceuticals Limited (ASX:CXS and NASDAQ:CXSP) announced today.
ATS Medical, Inc., manufacturer and marketer of state-of-the-art cardiac surgery products and services today announced the first commercial implants of the ATS 3f Enable® Aortic Bioprosthesis were recently performed at the University of Berne Hospital, Berne, Switzerland by Lars Englberger, MD, Mario Stalder, MD, and Professor Thierry Carrel. The procedures were completed using a sutureless technique and the patients are recovering with no complications.
Librede Inc. has joined the UCLA on-campus technology incubator space at the California NanoSystems Institute, where the startup company will work on developing technologies to improve ion channel drug discovery and screening.
Kensey Nash Corporation, a regenerative medicine company, today announced that it entered into a new two-year Supply Agreement with St. Jude Medical, Inc. for the period from January 1, 2011 to December 31, 2012. The agreement provides for Kensey Nash to be the exclusive outside supplier of collagen plugs, one of the key resorbable components of the Angio-Seal Vascular Closure Device, the leading arterial puncture closure product in the world.
› Verified 8 days ago
| Name | Rocky Mountain Hospice-butte |
|---|---|
| Location | 19 Discovery Dr, Butte, Montana |
| Hospice ID | 271530 |
| Category | Freestanding Hospice |
| Ownership Type | Proprietary - Corporation |
| Profit Type | FOR PROFIT |
| SSA county code | 460 |
News Archive
The most comprehensive analysis yet of breast cancer shows that one of the most deadly subtypes is genetically more similar to ovarian tumors than to other breast cancers.
Data showing the ability of omacetaxine to kill leukemic stem cells in mouse models with drug-resistant chronic myelogenous leukemia (CML) are the subject of an advance online publication in the journal Leukemia, ChemGenex Pharmaceuticals Limited (ASX:CXS and NASDAQ:CXSP) announced today.
ATS Medical, Inc., manufacturer and marketer of state-of-the-art cardiac surgery products and services today announced the first commercial implants of the ATS 3f Enable® Aortic Bioprosthesis were recently performed at the University of Berne Hospital, Berne, Switzerland by Lars Englberger, MD, Mario Stalder, MD, and Professor Thierry Carrel. The procedures were completed using a sutureless technique and the patients are recovering with no complications.
Librede Inc. has joined the UCLA on-campus technology incubator space at the California NanoSystems Institute, where the startup company will work on developing technologies to improve ion channel drug discovery and screening.
Kensey Nash Corporation, a regenerative medicine company, today announced that it entered into a new two-year Supply Agreement with St. Jude Medical, Inc. for the period from January 1, 2011 to December 31, 2012. The agreement provides for Kensey Nash to be the exclusive outside supplier of collagen plugs, one of the key resorbable components of the Angio-Seal Vascular Closure Device, the leading arterial puncture closure product in the world.
› Verified 8 days ago
| NPI Number | 1205008471 |
| Organization Name | Hospice Solutions Llc |
| Address | 19 Discovery Dr Butte, Montana, 59701 |
| Phone Number | (406)494-6114 |
News Archive
The most comprehensive analysis yet of breast cancer shows that one of the most deadly subtypes is genetically more similar to ovarian tumors than to other breast cancers.
Data showing the ability of omacetaxine to kill leukemic stem cells in mouse models with drug-resistant chronic myelogenous leukemia (CML) are the subject of an advance online publication in the journal Leukemia, ChemGenex Pharmaceuticals Limited (ASX:CXS and NASDAQ:CXSP) announced today.
ATS Medical, Inc., manufacturer and marketer of state-of-the-art cardiac surgery products and services today announced the first commercial implants of the ATS 3f Enable® Aortic Bioprosthesis were recently performed at the University of Berne Hospital, Berne, Switzerland by Lars Englberger, MD, Mario Stalder, MD, and Professor Thierry Carrel. The procedures were completed using a sutureless technique and the patients are recovering with no complications.
Librede Inc. has joined the UCLA on-campus technology incubator space at the California NanoSystems Institute, where the startup company will work on developing technologies to improve ion channel drug discovery and screening.
Kensey Nash Corporation, a regenerative medicine company, today announced that it entered into a new two-year Supply Agreement with St. Jude Medical, Inc. for the period from January 1, 2011 to December 31, 2012. The agreement provides for Kensey Nash to be the exclusive outside supplier of collagen plugs, one of the key resorbable components of the Angio-Seal Vascular Closure Device, the leading arterial puncture closure product in the world.
› Verified 8 days ago
| NPI Number | 1588982607 |
| Organization Name | Rocky Mountain Hospice Of Butte, Llc |
| Address | 19 Discovery Dr Butte, Montana, 59701 |
| Phone Number | (406)494-6114 |
News Archive
The most comprehensive analysis yet of breast cancer shows that one of the most deadly subtypes is genetically more similar to ovarian tumors than to other breast cancers.
Data showing the ability of omacetaxine to kill leukemic stem cells in mouse models with drug-resistant chronic myelogenous leukemia (CML) are the subject of an advance online publication in the journal Leukemia, ChemGenex Pharmaceuticals Limited (ASX:CXS and NASDAQ:CXSP) announced today.
ATS Medical, Inc., manufacturer and marketer of state-of-the-art cardiac surgery products and services today announced the first commercial implants of the ATS 3f Enable® Aortic Bioprosthesis were recently performed at the University of Berne Hospital, Berne, Switzerland by Lars Englberger, MD, Mario Stalder, MD, and Professor Thierry Carrel. The procedures were completed using a sutureless technique and the patients are recovering with no complications.
Librede Inc. has joined the UCLA on-campus technology incubator space at the California NanoSystems Institute, where the startup company will work on developing technologies to improve ion channel drug discovery and screening.
Kensey Nash Corporation, a regenerative medicine company, today announced that it entered into a new two-year Supply Agreement with St. Jude Medical, Inc. for the period from January 1, 2011 to December 31, 2012. The agreement provides for Kensey Nash to be the exclusive outside supplier of collagen plugs, one of the key resorbable components of the Angio-Seal Vascular Closure Device, the leading arterial puncture closure product in the world.
› Verified 8 days ago
| Quality Measure | Provider Score | National Score |
|---|---|---|
| Patients or caregivers who were asked about treatment preferences like hospitalization and resuscitation at the beginning of hospice care | 91.1 | 98.3 |
| Patients or caregivers who were asked about their beliefs and values at the beginning of hospice care | 80.3 | 93.6 |
| Patients who were checked for pain at the beginning of hospice care | 91.7 | 93.9 |
| Patients who got a timely and thorough pain assessment when pain was identified as a problem | 89.1 | 77.7 |
| Patients who were checked for shortness of breath at the beginning of hospice care | 94.6 | 97.3 |
| Patients who got timely treatment for shortness of breath | 80.4 | 94.6 |
| Patients taking opioid pain medication who were offered care for constipation | 91.1 | 93.3 |
News Archive
The most comprehensive analysis yet of breast cancer shows that one of the most deadly subtypes is genetically more similar to ovarian tumors than to other breast cancers.
Data showing the ability of omacetaxine to kill leukemic stem cells in mouse models with drug-resistant chronic myelogenous leukemia (CML) are the subject of an advance online publication in the journal Leukemia, ChemGenex Pharmaceuticals Limited (ASX:CXS and NASDAQ:CXSP) announced today.
ATS Medical, Inc., manufacturer and marketer of state-of-the-art cardiac surgery products and services today announced the first commercial implants of the ATS 3f Enable® Aortic Bioprosthesis were recently performed at the University of Berne Hospital, Berne, Switzerland by Lars Englberger, MD, Mario Stalder, MD, and Professor Thierry Carrel. The procedures were completed using a sutureless technique and the patients are recovering with no complications.
Librede Inc. has joined the UCLA on-campus technology incubator space at the California NanoSystems Institute, where the startup company will work on developing technologies to improve ion channel drug discovery and screening.
Kensey Nash Corporation, a regenerative medicine company, today announced that it entered into a new two-year Supply Agreement with St. Jude Medical, Inc. for the period from January 1, 2011 to December 31, 2012. The agreement provides for Kensey Nash to be the exclusive outside supplier of collagen plugs, one of the key resorbable components of the Angio-Seal Vascular Closure Device, the leading arterial puncture closure product in the world.
› Verified 8 days ago
| Home Health Aides | 3.5 |
| Counselors | 2.25 |
| Medical Social Workers | 1.6 |
| Physicians | 1.65 |
| Registered Nurses | 11.35 |
| Other Personnel | 8.25 |
| Total Employees | 28.6 |
|---|
News Archive
The most comprehensive analysis yet of breast cancer shows that one of the most deadly subtypes is genetically more similar to ovarian tumors than to other breast cancers.
Data showing the ability of omacetaxine to kill leukemic stem cells in mouse models with drug-resistant chronic myelogenous leukemia (CML) are the subject of an advance online publication in the journal Leukemia, ChemGenex Pharmaceuticals Limited (ASX:CXS and NASDAQ:CXSP) announced today.
ATS Medical, Inc., manufacturer and marketer of state-of-the-art cardiac surgery products and services today announced the first commercial implants of the ATS 3f Enable® Aortic Bioprosthesis were recently performed at the University of Berne Hospital, Berne, Switzerland by Lars Englberger, MD, Mario Stalder, MD, and Professor Thierry Carrel. The procedures were completed using a sutureless technique and the patients are recovering with no complications.
Librede Inc. has joined the UCLA on-campus technology incubator space at the California NanoSystems Institute, where the startup company will work on developing technologies to improve ion channel drug discovery and screening.
Kensey Nash Corporation, a regenerative medicine company, today announced that it entered into a new two-year Supply Agreement with St. Jude Medical, Inc. for the period from January 1, 2011 to December 31, 2012. The agreement provides for Kensey Nash to be the exclusive outside supplier of collagen plugs, one of the key resorbable components of the Angio-Seal Vascular Closure Device, the leading arterial puncture closure product in the world.
› Verified 8 days ago
| Homemakers | 0.3 |
| Total Volunteers | 0.3 |
|---|
News Archive
The most comprehensive analysis yet of breast cancer shows that one of the most deadly subtypes is genetically more similar to ovarian tumors than to other breast cancers.
Data showing the ability of omacetaxine to kill leukemic stem cells in mouse models with drug-resistant chronic myelogenous leukemia (CML) are the subject of an advance online publication in the journal Leukemia, ChemGenex Pharmaceuticals Limited (ASX:CXS and NASDAQ:CXSP) announced today.
ATS Medical, Inc., manufacturer and marketer of state-of-the-art cardiac surgery products and services today announced the first commercial implants of the ATS 3f Enable® Aortic Bioprosthesis were recently performed at the University of Berne Hospital, Berne, Switzerland by Lars Englberger, MD, Mario Stalder, MD, and Professor Thierry Carrel. The procedures were completed using a sutureless technique and the patients are recovering with no complications.
Librede Inc. has joined the UCLA on-campus technology incubator space at the California NanoSystems Institute, where the startup company will work on developing technologies to improve ion channel drug discovery and screening.
Kensey Nash Corporation, a regenerative medicine company, today announced that it entered into a new two-year Supply Agreement with St. Jude Medical, Inc. for the period from January 1, 2011 to December 31, 2012. The agreement provides for Kensey Nash to be the exclusive outside supplier of collagen plugs, one of the key resorbable components of the Angio-Seal Vascular Closure Device, the leading arterial puncture closure product in the world.
› Verified 8 days ago
| Highland Hospice Location: 3703 Harrison Ave, Butte, Montana, 59701 Phone: (406) 494-6114 |
| Rocky Mountain Hospice-butte Location: 19 Discovery Dr, Butte, Montana, 59701 Phone: (406) 494-6114 |